Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"hoffmann-la roche ltd" d.s.d. podgorica - mosunetuzumab - koncentrat za rastvor za infuziju - 1mg

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"hoffmann-la roche ltd" d.s.d. podgorica - mosunetuzumab - koncentrat za rastvor za infuziju - 30mg

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 2,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 2,5 mg lenalidomida

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

amicus pharma doo podgorica - bendamustin - prašak za koncentrat za rastvor za infuziju - 25mg

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

amicus pharma doo podgorica - bendamustin - prašak za koncentrat za rastvor za infuziju - 25mg

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

amicus pharma doo podgorica - bendamustin - prašak za koncentrat za rastvor za infuziju - 100mg

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

amicus pharma doo podgorica - bendamustin - prašak za koncentrat za rastvor za infuziju - 100mg

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - bendamustin - prašak za koncentrat za otopinu za infuziju - 25 mg/1 viala - 1 bočica sa praškom za koncentrat za otopinu za infuziju sadrži: 25 mg bendamustin (u obliku bendamustinhidrohlorida) 25 mg (2,5 mg/ml)